Processa Pharmaceuticals(US:PCSA) Benzingaยท2025-10-08 07:40Core Insights - Processa Pharmaceuticals Inc. (NASDAQ:PCSA) shares experienced a significant increase of 37.5% to $0.50 in after-hours trading, following a 29.03% gain during the regular session, closing at $0.36 [1] - Despite the recent surge, the company has faced challenges, with shares down 71.43% over the past year and 59.09% year to date, although there has been a 50% gain over the last six months [2] Clinical Development - Processa Pharmaceuticals is conducting a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a treatment for advanced or metastatic breast cancer, with the first patient treated in October 2024 [3] - The trial is a global, multicenter study comparing two doses of NGC-Cap with the FDA-approved drug capecitabine, involving 60 to 90 patients [3] - Interim analysis results are expected to be announced in mid-2025, as stated by David Young, President of Research and Development [4] Market Context - Breast cancer represents a significant market opportunity, with over 2 million cases diagnosed globally in 2022 and a five-year survival rate of approximately 30% for metastatic cases [6] - For the second quarter, Processa reported a loss of $0.25 per share, which was wider than the expected loss of $0.23, and the company generated no revenue during that quarter [6] - The third-quarter earnings report is scheduled for October 29 [6] Stock Performance - Over the past year, PCSA shares have traded between $0.15 and $1.50, with an average daily trading volume of 3.95 million shares and a market capitalization of $18.06 million [7] - Current trends indicate that PCSA is experiencing long-term consolidation according to Benzinga's Edge Stock Rankings [7]